Con amplia experiencia en diferentes perfiles de transacciones y tesis, conocemos profundamente a los compradores del sector salud, incluidos fondos y estratégicos, en Brasil y en el exterior.
Transacciones concluidas en este sector
Países donde se realizaron las transacciones
Especialistas dedicados a este sector
ferias comerciales, exhibiciones y conferencias mapeadas globalmente
bilhões de reais transacionados com fundos de investimento internacionais
Context
Vydence Medical is a leading company in the medical aesthetics market, with more than 30 years of experience and recognized for its comprehensive portfolio of high-tech equipment and strong capacity for innovation. Its factory, located in São Carlos (SP), specializes in producing laser equipment focused on dermatology, vascular surgery, and plastic surgery. With a consolidated international presence, the company exports to more than 30 countries, including the United States and Europe.
Grupo MedSystems, which counts XP as an investment partner, is a leader in the global medical aesthetics market, with a strong focus on innovation and international expansion.
Strategic Rationale
The acquisition of Vydence Medical by Grupo MedSystems strengthens MedSystems’ leadership in the global medical aesthetics market and significantly expands its innovation potential. By incorporating Vydence’s expertise, technology portfolio, and international presence, MedSystems enhances its ability to serve clients across different regions of the world and consolidates its position as one of the leading global players in high-performance medical aesthetics solutions.
The transaction also reinforces MedSystems’ strategy of sustainable growth and internationalization, while opening new opportunities for Vydence to continue developing cutting-edge technology with global reach.
Context
Founded in 1987 in Rio de Janeiro, Plastlabor has distinguished itself over the years as one of the leading suppliers of laboratory and scientific products for microbiological analyses in Brazil.
With a comprehensive portfolio that includes ready-to-use culture media, disposable products, biosafety items, swabs, and laboratory accessories, the company has consolidated its market position, serving over 1,200 clients in laboratories, hospitals, food industries, and more.
Strategic Rationale
The acquisition by Solabia reinforces the group's strategy to expand its presence in the Brazilian market and strengthen its offering of solutions for microbiological investigations and the maintenance and transport of biological material. With this transaction, Solabia aims to integrate Plastlabor's capabilities with its own advanced technologies, creating synergies with its current subsidiary Laborclin, which will further benefit its clients and partners.
Context
CT Group, a leading distributor of surgical and medical devices in Brazil, has been invested in by Bunzl plc, the specialist international distribution and services Group.
Founded in 1997, CT Group is a national leader in the surgical and medical device market in Brazil, with a focus on neurosurgery and spinal area.
CT Group connects exclusive and premium manufacturers with a wide range of hospitals and insurance companies throughout the country. The company has built a strong reputation for delivering innovative and high-quality medical devices, ensuring reliable supply and specialized logistics to meet the industry's demands.
Bunzl plc is the global leader in value-added distribution and continues to expand its operations in over 30 countries across the Americas, Europe, Asia Pacific, and the UK & Ireland. With a workforce exceeding 20,000 employees worldwide, the company is aleading player in the distribution of healthcare, hygiene, safety, grocery, and food service products.
Strategic Rationale
The investment in CT Group, which was advised by igc partners, will boost Bunzl’s growth in Brazil in the medical devices segment, in addition to expanding its geographic presence in the health market.
Context
Grupo JL Health is a holding company operating in the dermatology, plastic surgery, and ophthalmology segments, with offices in Brazil, Colombia, and Argentina. Among its companies is MedSystems, the largest distributor and importer of medical equipment for dermatological treatment, health, and wellness in Latin America, with over 20 years of experience in the sector.
The group also includes MedBanking, a platform that provides financial solutions for healthcare companies and professionals, and Med Academy, focused on training and educational programs for the dermatology and plastic surgery markets. With an end-to-end provider model, JL Health covers the entire value chain — from curation and regulatory processes to technical support — and reported R$ 520 million in revenue in 2022, with expectations to reach R$ 700 million in 2023.
XP Private Equity, the private equity investment arm of XP, acquired a minority stake in the company in one of the largest transactions ever carried out in Brazil by a private equity fund in the dermatological technology sector.
Strategic Rationale
The investment by XP Private Equity will enable Grupo JL Health to accelerate both its organic and inorganic growth plans. Key priorities include strengthening areas where it already operates more discreetly and expanding into new high-potential segments such as gynecology, ophthalmology, and orthopedics.
The partnership also enhances the holding company’s financial and strategic capacity to expand its portfolio and consolidate its leadership position as the leading integrated medical technology platform specializing in aesthetics, health, and wellness in Latin America.
Context
Laboratório Homeopático Almeida Prado is a leading Brazilian homeopathic pharmaceutical company, founded in 1959 in São Paulo by homeopath and researcher Estevam José de Almeida Prado and pharmacist Rubens Gimenes. A pioneer in industrialized homeopathy in Brazil, the company became known for launching a line of homeopathic medicines modeled after European and North American standards. Today, Almeida Prado is a benchmark in the homeopathic pharmaceutical industry, recognized for producing effective and safe homeopathic medicines.
Headquartered in Uruguay, Megalabs is one of the largest pharmaceutical companies in Latin America, with operations in 18 countries, over 8,000 employees, and a portfolio of more than 1,800 products. Since 2016, Megalabs has been strengthening its presence in Brazil through product launches, acquisitions, licenses, and partnerships, building a strong position in the country’s pharmaceutical market.
Strategic Rationale
The acquisition of Almeida Prado’s recognized and traditional product, Complexo 46 (AP46), strengthens Megalabs’ market position in the gastroenterology segment and expands its over-the-counter (OTC) portfolio in Brazil. This transaction allows Megalabs to leverage AP46’s brand equity and long-standing consumer trust, boosting sales and reinforcing its growth strategy in the Brazilian OTC and gastroenterology markets.
Context
Blue Health is a leading provider of medical equipment solutions, operating in the rental, maintenance, and sale of imaging equipment, as well as reagents for in vitro diagnostics. With more than 20 years of experience, the company has established itself as one of the largest healthcare solution ecosystems in Brazil, with a strong presence in cutting-edge technology and personalized services. In June 2022, it received a R$ 200 million investment from Kinea Private Equity, the private equity arm of the Itaú group, in exchange for a minority stake.
Strategic Rationale
The investment from Kinea will enable Blue Health to accelerate its organic and inorganic expansion plan in a highly fragmented market with significant growth potential. The transaction enhances the company’s ability to broaden its operations, consolidate its presence in new healthcare niches, and strengthen its infrastructure, further establishing itself as a benchmark in imaging diagnostics and medical services in Brazil.
Context
Founded in 1996, Prontmed specializes in providing structured clinical data through electronic medical records to support population health management. Currently used by around 7,000 physicians across Brazil, the platform integrates clinical information and generates intelligence tailored to the needs of different medical specialties.
The Fleury and Sabin Groups, national references in diagnostic medicine, acquired a combined 30% minority stake in Prontmed.
Strategic Rationale
The investment will enable Prontmed to expand its user base, accelerate the development of new features, and reinforce its position as a reference in structured clinical data in Brazil. For Fleury and Sabin, the transaction enhances their ability to offer integrated, evidence-based solutions, strengthening healthcare efficiency and the integration of medical data on a national scale.
Context
BSN Medical, part of the Essity Group, is a global developer, manufacturer, and distributor of medical products in the areas of wound care, compression therapy, and orthopedics. Neve Indústria e Comércio de Produtos Cirúrgicos, founded in 1986 and headquartered in Bragança Paulista (SP), manufactures surgical, orthopedic, protective, and hospital apparel product lines. It serves over 1,500 hospitals and employs approximately 400 people.
Strategic Rationale
In August 2019, BSN Medical sold all assets of its Neve division to a group of Brazilian investors. The transaction allowed BSN to focus on its core global strategy, while Neve gained greater operational autonomy under local management, maintaining domestic production and direct service to the hospital market.
Context
Onofre is one of the most traditional pharmacy chains in Brazil, with more than 85 years of history. It currently operates 50 stores across the country’s main states and was a pioneer in online retail, establishing itself as a digital pharmacy. Recognized for its expertise in e-commerce and telesales with delivery, Onofre has become one of the leaders in this channel, which represents a significant portion of its revenue.
The transaction involved the sale of Onofre by CVS Health, one of the largest health and wellness chains in the world, to RaiaDrogasil, the largest pharmaceutical retail group in Brazil.
Strategic Rationale
The acquisition strengthens RaiaDrogasil’s position as the leader in the Brazilian pharmaceutical sector, adding Onofre’s expertise in digital channels and expanding its ability to deliver convenience and omnichannel experiences to customers. For Onofre, the transaction represents the opportunity to integrate into a larger structure, reinforcing its presence in both physical and digital retail and expanding its reach in the national market.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women's health, currently operating five units in São Paulo. Founded by doctors Professor Dr. Rogério Ciarcia Ramires and Professor Dr. Décio Roveda Júnior, Femme offers services including diagnostic gynecology, ultrasound, fetal medicine, breast imaging, genetic testing, pathology, and blood tests.
L Catterton is the world’s largest consumer-focused private equity firm, founded as a joint venture between Catterton, LVMH, and Groupe Arnault. It manages over US $15 billion across multiple funds focused on the consumer and health sectors.
Strategic Rationale
L Catterton’s investment is intended to fuel Femme’s national expansion by scaling its clinic network, adding new services, and enhancing marketing efforts. The strategic partnership leverages L Catterton’s deep expertise in growing consumer-health platforms across Latin America, positioning Femme to elevate its brand and accelerate growth.
Context
Poupafarma is a pharmacy retail chain with a presence in more than 30 cities, offering a wide portfolio of medicines, health, and wellness products. Over the years, it has established itself as a relevant brand in the sector, with a focus on convenience and customer proximity.
The transaction involved the sale of a majority stake to InvestFarma, an investment vehicle of Stratus Capital Partners, a middle-market private equity fund specialized in supporting companies in stages of growth and transformation.
Strategic Rationale
The entry of Stratus as Poupafarma’s controlling shareholder will accelerate the expansion of the chain, strengthen its governance, and optimize its operations, increasing competitiveness in a highly fragmented and competitive sector. The investment also enables the exploration of strategic synergies, expansion into new regions, and the consolidation of Poupafarma’s position as one of the leading pharmacy chains in Brazil.
Context
Divcom Pharma is a pharmaceutical company with a strong presence in the over-the-counter (OTC) and supplements market, recognized for its well-established health and wellness brands.
FQM Farmoquímica is one of the traditional companies in the Brazilian pharmaceutical sector, with a diversified portfolio that includes prescription drugs, OTC products, dermocosmetics, and dietary supplements, serving multiple medical specialties.
With the merger of operations, FQM Divcom is created, combining the strength of two relevant players in the industry and significantly expanding its reach in the Brazilian pharmaceutical market.
Strategic Rationale
The integration of Divcom Pharma and FQM Farmoquímica strengthens the competitiveness of the new group, broadening its product portfolio and enhancing its presence with physicians, pharmacies, and consumers across Brazil.
The creation of FQM Divcom enables the capture of commercial and operational synergies, accelerates the expansion of well-established brands, and supports investment in the development of new products, consolidating the company as one of the main players in the Brazilian pharmaceutical sector.
Context
Osler Laboratory, a Brazilian manufacturer of insect repellents, is best known for its Exposis® brand, a premium line of picaridin-based products widely sold in pharmacies across Brazil. The company built a strong reputation in the Brazilian market for effective, high-quality repellents targeted at consumers seeking advanced protection.
SC Johnson, headquartered in Racine, Wisconsin (USA), is a global leader in household and personal care products. Founded in 1886, SC Johnson owns iconic brands like OFF!®, Raid®, Glade®, Windex®, and Pledge®, and operates in over 70 countries.
Strategic Rationale
The acquisition of Osler Laboratory enables SC Johnson to strengthen its insect-repellent portfolio in Brazil, adding a premium, locally recognized brand to complement its existing pest-control products. The transaction expands SC Johnson’s footprint in Brazil and enhances its ability to meet consumer needs in the insect protection segment.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women’s health, with units in São Paulo and services that include diagnostic gynecology, fetal medicine, breast imaging, genetic testing, pathology, and laboratory exams. Founded by specialist physicians, Femme has established itself as a reference in the segment, with a strong focus on innovation and quality of care.
Casa de Gestão is an independent asset manager that invests in high-growth potential companies in Brazil.
Strategic Rationale
The investment from Casa de Gestão will enable Femme to accelerate its expansion, strengthen its governance structure, and broaden its portfolio of women’s health services. The partnership also reinforces the laboratory’s positioning as a reference in specialized diagnostics, supporting sustainable growth and differentiation in the healthcare market.
Context
CPO – Centro Paulista de Oncologia is one of the reference clinics for cancer treatment in Brazil, with a strong presence in providing integrated and multidisciplinary care to oncology patients. With a highly specialized medical team and a focus on clinical excellence, CPO has established itself as one of the country’s leading private oncology centers.
Grupo OncoClínicas do Brasil is one of the largest oncology networks in Latin America, with nationwide presence through dozens of clinics, hospitals, and cancer treatment centers. Founded in 2010, the group brings together more than 2,700 specialist physicians and has a mission to deliver high-quality care and access to cutting-edge medicine, integrating assistance, education, and research in oncology.
Context
Drogarias DPSP S/A is one of the largest pharmaceutical retail chains in Brazil, formed through the merger of the Drogaria São Paulo and Drogarias Pacheco brands. The company operates in several regions across the country, with thousands of stores, offering a wide portfolio of medicines and health and wellness products.
Vila Inhambu, a minority shareholder of DPSP, sold its stake to the company’s controlling shareholders, reinforcing the group’s ownership structure.
Context
Psimon is a company specialized in health and wellness solutions, focused on the development and supply of high-quality products for medical and hospital care. Throughout its history, it has established itself as a trusted partner for healthcare institutions through product reliability and innovation.
Cremer, with more than 85 years of history, is the national leader in the manufacturing and distribution of products for first aid, personal care, and hospital use.
Context
LM Farma Indústria e Comércio Ltda., founded in 1988 and based in São José dos Campos (SP), is a Brazilian manufacturer of wound care products under the Curatec brand. Before 2011, it had built a strong presence in hospital markets with R&D-driven antiseptic dressings.
Laboratoires Urgo, part of the French Urgo Group founded in 1880, specializes in wound care and advanced healing solutions.
Strategic Rationale
The acquisition provided Urgo with local manufacturing, ANVISA certification, and an established distribution network, enabling quicker market entry and regulatory compliance in Brazil. LM Farma became Urgo’s regional platform for introducing its global wound-care portfolio, accelerating R&D investments and product expansion in Latin America.
Context
Hypermarcas is one of Brazil’s largest consumer goods and pharmaceutical companies, with a diversified portfolio that includes prescription drugs, generics, consumer products, and personal care items.
Farmasa, controlled by the Samaja Family, is a traditional Brazilian pharmaceutical company with strong expertise in prescription drugs and health products. Recognized for its quality and long-standing presence in the national market, it has established itself as a reference in the pharmaceutical sector.
Strategic Rationale
The merger between Hypermarcas and Farmasa, carried out through a share swap, strengthens Hypermarcas’ position as one of the leading pharmaceutical companies in Brazil. The transaction expands its product portfolio, generates operational synergies, and accelerates its expansion in the prescription drug market. For Farmasa, the deal provided access to greater scale, infrastructure, and distribution capacity, consolidating the union as a strategic move to lead growth in the sector.
Context
Farmasa (Laboratório Americano de Farmacoterapia S.A.) is a Brazilian pharmaceutical company specializing in high-growth prescription and direct-to-consumer medications. In November 2007, GP Investments, a major Brazilian private equity firm, acquired a significant minority stake in Farmasa through an investment and association agreement, which also included a subsequent merger with Hypermarcas, a leading Brazilian consumer health company.
Strategic Rationale
GP Investments’ stake enabled Farmasa to leverage synergies from the merger with Hypermarcas—strengthening its distribution reach, product portfolio, and operational scale. The combination created a more robust platform in Brazil’s pharmaceutical and consumer health market, positioning the merged entity for sustained growth.
Intente cambiar los filtros y vuelva a realizar la búsqueda
Adaptamos los 28 años de experiencia de IGC para crear un proceso tailor-made para el sector, ya sea en M&A o fundraising. Actuamos con diferentes perfiles de transacciones y tesis, con un equipo especializado que garantiza una dinámica estratégica de estructuración, abordaje y negociación.
Transacciones en fundraising.
Mil millones de reales transaccionados con fondos nacionales e internacionales.
Actuamos con una amplia red de compradores estratégicos e inversionistas financieros a nivel global, incluyendo fondos de private equity, family offices y compañías multinacionales de diversos sectores.
Actuamos con una amplia red de compradores estratégicos e inversores financieros a nivel global, incluyendo fondos de private equity, growth, venture capital y compañías multinacionales de diversos sectores.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Context
Onofre is one of the most traditional pharmacy chains in Brazil, with more than 85 years of history. It currently operates 50 stores across the country’s main states and was a pioneer in online retail, establishing itself as a digital pharmacy. Recognized for its expertise in e-commerce and telesales with delivery, Onofre has become one of the leaders in this channel, which represents a significant portion of its revenue.
The transaction involved the sale of Onofre by CVS Health, one of the largest health and wellness chains in the world, to RaiaDrogasil, the largest pharmaceutical retail group in Brazil.
Strategic Rationale
The acquisition strengthens RaiaDrogasil’s position as the leader in the Brazilian pharmaceutical sector, adding Onofre’s expertise in digital channels and expanding its ability to deliver convenience and omnichannel experiences to customers. For Onofre, the transaction represents the opportunity to integrate into a larger structure, reinforcing its presence in both physical and digital retail and expanding its reach in the national market.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women's health, currently operating five units in São Paulo. Founded by doctors Professor Dr. Rogério Ciarcia Ramires and Professor Dr. Décio Roveda Júnior, Femme offers services including diagnostic gynecology, ultrasound, fetal medicine, breast imaging, genetic testing, pathology, and blood tests.
L Catterton is the world’s largest consumer-focused private equity firm, founded as a joint venture between Catterton, LVMH, and Groupe Arnault. It manages over US $15 billion across multiple funds focused on the consumer and health sectors.
Strategic Rationale
L Catterton’s investment is intended to fuel Femme’s national expansion by scaling its clinic network, adding new services, and enhancing marketing efforts. The strategic partnership leverages L Catterton’s deep expertise in growing consumer-health platforms across Latin America, positioning Femme to elevate its brand and accelerate growth.
Context
Osler Laboratory, a Brazilian manufacturer of insect repellents, is best known for its Exposis® brand, a premium line of picaridin-based products widely sold in pharmacies across Brazil. The company built a strong reputation in the Brazilian market for effective, high-quality repellents targeted at consumers seeking advanced protection.
SC Johnson, headquartered in Racine, Wisconsin (USA), is a global leader in household and personal care products. Founded in 1886, SC Johnson owns iconic brands like OFF!®, Raid®, Glade®, Windex®, and Pledge®, and operates in over 70 countries.
Strategic Rationale
The acquisition of Osler Laboratory enables SC Johnson to strengthen its insect-repellent portfolio in Brazil, adding a premium, locally recognized brand to complement its existing pest-control products. The transaction expands SC Johnson’s footprint in Brazil and enhances its ability to meet consumer needs in the insect protection segment.
Context
Farmasa (Laboratório Americano de Farmacoterapia S.A.) is a Brazilian pharmaceutical company specializing in high-growth prescription and direct-to-consumer medications. In November 2007, GP Investments, a major Brazilian private equity firm, acquired a significant minority stake in Farmasa through an investment and association agreement, which also included a subsequent merger with Hypermarcas, a leading Brazilian consumer health company.
Strategic Rationale
GP Investments’ stake enabled Farmasa to leverage synergies from the merger with Hypermarcas—strengthening its distribution reach, product portfolio, and operational scale. The combination created a more robust platform in Brazil’s pharmaceutical and consumer health market, positioning the merged entity for sustained growth.
Actuamos con una amplia red de compradores estratégicos e inversionistas financieros a nivel global, incluyendo fondos de private equity, family offices y compañías multinacionales de diversos sectores.
Actuamos con una amplia red de compradores estratégicos e inversores financieros a nivel global, incluyendo fondos de private equity, growth, venture capital y compañías multinacionales de diversos sectores.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Context
Hypermarcas is one of Brazil’s largest consumer goods and pharmaceutical companies, with a diversified portfolio that includes prescription drugs, generics, consumer products, and personal care items.
Farmasa, controlled by the Samaja Family, is a traditional Brazilian pharmaceutical company with strong expertise in prescription drugs and health products. Recognized for its quality and long-standing presence in the national market, it has established itself as a reference in the pharmaceutical sector.
Strategic Rationale
The merger between Hypermarcas and Farmasa, carried out through a share swap, strengthens Hypermarcas’ position as one of the leading pharmaceutical companies in Brazil. The transaction expands its product portfolio, generates operational synergies, and accelerates its expansion in the prescription drug market. For Farmasa, the deal provided access to greater scale, infrastructure, and distribution capacity, consolidating the union as a strategic move to lead growth in the sector.
Context
Psimon is a company specialized in health and wellness solutions, focused on the development and supply of high-quality products for medical and hospital care. Throughout its history, it has established itself as a trusted partner for healthcare institutions through product reliability and innovation.
Cremer, with more than 85 years of history, is the national leader in the manufacturing and distribution of products for first aid, personal care, and hospital use.
Context
CPO – Centro Paulista de Oncologia is one of the reference clinics for cancer treatment in Brazil, with a strong presence in providing integrated and multidisciplinary care to oncology patients. With a highly specialized medical team and a focus on clinical excellence, CPO has established itself as one of the country’s leading private oncology centers.
Grupo OncoClínicas do Brasil is one of the largest oncology networks in Latin America, with nationwide presence through dozens of clinics, hospitals, and cancer treatment centers. Founded in 2010, the group brings together more than 2,700 specialist physicians and has a mission to deliver high-quality care and access to cutting-edge medicine, integrating assistance, education, and research in oncology.
Context
Drogarias DPSP S/A is one of the largest pharmaceutical retail chains in Brazil, formed through the merger of the Drogaria São Paulo and Drogarias Pacheco brands. The company operates in several regions across the country, with thousands of stores, offering a wide portfolio of medicines and health and wellness products.
Vila Inhambu, a minority shareholder of DPSP, sold its stake to the company’s controlling shareholders, reinforcing the group’s ownership structure.
Context
Femme Laboratório da Mulher is a diagnostic center exclusively focused on women’s health, with units in São Paulo and services that include diagnostic gynecology, fetal medicine, breast imaging, genetic testing, pathology, and laboratory exams. Founded by specialist physicians, Femme has established itself as a reference in the segment, with a strong focus on innovation and quality of care.
Casa de Gestão is an independent asset manager that invests in high-growth potential companies in Brazil.
Strategic Rationale
The investment from Casa de Gestão will enable Femme to accelerate its expansion, strengthen its governance structure, and broaden its portfolio of women’s health services. The partnership also reinforces the laboratory’s positioning as a reference in specialized diagnostics, supporting sustainable growth and differentiation in the healthcare market.
Context
Divcom Pharma is a pharmaceutical company with a strong presence in the over-the-counter (OTC) and supplements market, recognized for its well-established health and wellness brands.
FQM Farmoquímica is one of the traditional companies in the Brazilian pharmaceutical sector, with a diversified portfolio that includes prescription drugs, OTC products, dermocosmetics, and dietary supplements, serving multiple medical specialties.
With the merger of operations, FQM Divcom is created, combining the strength of two relevant players in the industry and significantly expanding its reach in the Brazilian pharmaceutical market.
Strategic Rationale
The integration of Divcom Pharma and FQM Farmoquímica strengthens the competitiveness of the new group, broadening its product portfolio and enhancing its presence with physicians, pharmacies, and consumers across Brazil.
The creation of FQM Divcom enables the capture of commercial and operational synergies, accelerates the expansion of well-established brands, and supports investment in the development of new products, consolidating the company as one of the main players in the Brazilian pharmaceutical sector.
Context
Poupafarma is a pharmacy retail chain with a presence in more than 30 cities, offering a wide portfolio of medicines, health, and wellness products. Over the years, it has established itself as a relevant brand in the sector, with a focus on convenience and customer proximity.
The transaction involved the sale of a majority stake to InvestFarma, an investment vehicle of Stratus Capital Partners, a middle-market private equity fund specialized in supporting companies in stages of growth and transformation.
Strategic Rationale
The entry of Stratus as Poupafarma’s controlling shareholder will accelerate the expansion of the chain, strengthen its governance, and optimize its operations, increasing competitiveness in a highly fragmented and competitive sector. The investment also enables the exploration of strategic synergies, expansion into new regions, and the consolidation of Poupafarma’s position as one of the leading pharmacy chains in Brazil.
Context
Founded in 1996, Prontmed specializes in providing structured clinical data through electronic medical records to support population health management. Currently used by around 7,000 physicians across Brazil, the platform integrates clinical information and generates intelligence tailored to the needs of different medical specialties.
The Fleury and Sabin Groups, national references in diagnostic medicine, acquired a combined 30% minority stake in Prontmed.
Strategic Rationale
The investment will enable Prontmed to expand its user base, accelerate the development of new features, and reinforce its position as a reference in structured clinical data in Brazil. For Fleury and Sabin, the transaction enhances their ability to offer integrated, evidence-based solutions, strengthening healthcare efficiency and the integration of medical data on a national scale.
Context
Blue Health is a leading provider of medical equipment solutions, operating in the rental, maintenance, and sale of imaging equipment, as well as reagents for in vitro diagnostics. With more than 20 years of experience, the company has established itself as one of the largest healthcare solution ecosystems in Brazil, with a strong presence in cutting-edge technology and personalized services. In June 2022, it received a R$ 200 million investment from Kinea Private Equity, the private equity arm of the Itaú group, in exchange for a minority stake.
Strategic Rationale
The investment from Kinea will enable Blue Health to accelerate its organic and inorganic expansion plan in a highly fragmented market with significant growth potential. The transaction enhances the company’s ability to broaden its operations, consolidate its presence in new healthcare niches, and strengthen its infrastructure, further establishing itself as a benchmark in imaging diagnostics and medical services in Brazil.
Context
Grupo JL Health is a holding company operating in the dermatology, plastic surgery, and ophthalmology segments, with offices in Brazil, Colombia, and Argentina. Among its companies is MedSystems, the largest distributor and importer of medical equipment for dermatological treatment, health, and wellness in Latin America, with over 20 years of experience in the sector.
The group also includes MedBanking, a platform that provides financial solutions for healthcare companies and professionals, and Med Academy, focused on training and educational programs for the dermatology and plastic surgery markets. With an end-to-end provider model, JL Health covers the entire value chain — from curation and regulatory processes to technical support — and reported R$ 520 million in revenue in 2022, with expectations to reach R$ 700 million in 2023.
XP Private Equity, the private equity investment arm of XP, acquired a minority stake in the company in one of the largest transactions ever carried out in Brazil by a private equity fund in the dermatological technology sector.
Strategic Rationale
The investment by XP Private Equity will enable Grupo JL Health to accelerate both its organic and inorganic growth plans. Key priorities include strengthening areas where it already operates more discreetly and expanding into new high-potential segments such as gynecology, ophthalmology, and orthopedics.
The partnership also enhances the holding company’s financial and strategic capacity to expand its portfolio and consolidate its leadership position as the leading integrated medical technology platform specializing in aesthetics, health, and wellness in Latin America.
Context
Vydence Medical is a leading company in the medical aesthetics market, with more than 30 years of experience and recognized for its comprehensive portfolio of high-tech equipment and strong capacity for innovation. Its factory, located in São Carlos (SP), specializes in producing laser equipment focused on dermatology, vascular surgery, and plastic surgery. With a consolidated international presence, the company exports to more than 30 countries, including the United States and Europe.
Grupo MedSystems, which counts XP as an investment partner, is a leader in the global medical aesthetics market, with a strong focus on innovation and international expansion.
Strategic Rationale
The acquisition of Vydence Medical by Grupo MedSystems strengthens MedSystems’ leadership in the global medical aesthetics market and significantly expands its innovation potential. By incorporating Vydence’s expertise, technology portfolio, and international presence, MedSystems enhances its ability to serve clients across different regions of the world and consolidates its position as one of the leading global players in high-performance medical aesthetics solutions.
The transaction also reinforces MedSystems’ strategy of sustainable growth and internationalization, while opening new opportunities for Vydence to continue developing cutting-edge technology with global reach.
Context
Laboratório Homeopático Almeida Prado is a leading Brazilian homeopathic pharmaceutical company, founded in 1959 in São Paulo by homeopath and researcher Estevam José de Almeida Prado and pharmacist Rubens Gimenes. A pioneer in industrialized homeopathy in Brazil, the company became known for launching a line of homeopathic medicines modeled after European and North American standards. Today, Almeida Prado is a benchmark in the homeopathic pharmaceutical industry, recognized for producing effective and safe homeopathic medicines.
Headquartered in Uruguay, Megalabs is one of the largest pharmaceutical companies in Latin America, with operations in 18 countries, over 8,000 employees, and a portfolio of more than 1,800 products. Since 2016, Megalabs has been strengthening its presence in Brazil through product launches, acquisitions, licenses, and partnerships, building a strong position in the country’s pharmaceutical market.
Strategic Rationale
The acquisition of Almeida Prado’s recognized and traditional product, Complexo 46 (AP46), strengthens Megalabs’ market position in the gastroenterology segment and expands its over-the-counter (OTC) portfolio in Brazil. This transaction allows Megalabs to leverage AP46’s brand equity and long-standing consumer trust, boosting sales and reinforcing its growth strategy in the Brazilian OTC and gastroenterology markets.
Actuamos con una amplia red de compradores estratégicos e inversionistas financieros a nivel global, incluyendo fondos de private equity, family offices y compañías multinacionales de diversos sectores.
Actuamos con una amplia red de compradores estratégicos e inversores financieros a nivel global, incluyendo fondos de private equity, growth, venture capital y compañías multinacionales de diversos sectores.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Context
CT Group, a leading distributor of surgical and medical devices in Brazil, has been invested in by Bunzl plc, the specialist international distribution and services Group.
Founded in 1997, CT Group is a national leader in the surgical and medical device market in Brazil, with a focus on neurosurgery and spinal area.
CT Group connects exclusive and premium manufacturers with a wide range of hospitals and insurance companies throughout the country. The company has built a strong reputation for delivering innovative and high-quality medical devices, ensuring reliable supply and specialized logistics to meet the industry's demands.
Bunzl plc is the global leader in value-added distribution and continues to expand its operations in over 30 countries across the Americas, Europe, Asia Pacific, and the UK & Ireland. With a workforce exceeding 20,000 employees worldwide, the company is aleading player in the distribution of healthcare, hygiene, safety, grocery, and food service products.
Strategic Rationale
The investment in CT Group, which was advised by igc partners, will boost Bunzl’s growth in Brazil in the medical devices segment, in addition to expanding its geographic presence in the health market.
Context
LM Farma Indústria e Comércio Ltda., founded in 1988 and based in São José dos Campos (SP), is a Brazilian manufacturer of wound care products under the Curatec brand. Before 2011, it had built a strong presence in hospital markets with R&D-driven antiseptic dressings.
Laboratoires Urgo, part of the French Urgo Group founded in 1880, specializes in wound care and advanced healing solutions.
Strategic Rationale
The acquisition provided Urgo with local manufacturing, ANVISA certification, and an established distribution network, enabling quicker market entry and regulatory compliance in Brazil. LM Farma became Urgo’s regional platform for introducing its global wound-care portfolio, accelerating R&D investments and product expansion in Latin America.
Context
BSN Medical, part of the Essity Group, is a global developer, manufacturer, and distributor of medical products in the areas of wound care, compression therapy, and orthopedics. Neve Indústria e Comércio de Produtos Cirúrgicos, founded in 1986 and headquartered in Bragança Paulista (SP), manufactures surgical, orthopedic, protective, and hospital apparel product lines. It serves over 1,500 hospitals and employs approximately 400 people.
Strategic Rationale
In August 2019, BSN Medical sold all assets of its Neve division to a group of Brazilian investors. The transaction allowed BSN to focus on its core global strategy, while Neve gained greater operational autonomy under local management, maintaining domestic production and direct service to the hospital market.
Actuamos con una amplia red de compradores estratégicos e inversionistas financieros a nivel global, incluyendo fondos de private equity, family offices y compañías multinacionales de diversos sectores.
Actuamos con una amplia red de compradores estratégicos e inversores financieros a nivel global, incluyendo fondos de private equity, growth, venture capital y compañías multinacionales de diversos sectores.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
Seguimos de cerca la evolución de las principales tesis sectoriales y perfiles de transacción. En los últimos años, hemos liderado diversas transacciones relevantes, conectando compradores globales con el sector.
igc es líder en transacciones en el sector salud, con destaque en las verticales de productos y servicios. Entendemos las dinámicas de cada mercado y, gracias a la especialización sectorial de los equipos, nos adaptamos a las particularidades de cada uno de ellos.
igc ha sido parte de la trayectoria de algunos de los empresarios más destacados de Brasil, liderando transacciones en múltiples sectores, siempre al lado del emprendedor.
“IGC siempre se preocupó por nuestro negocio, defendió con total determinación lo que era importante para nosotros como accionistas y supo crear valor para la compañía. Es fundamental contar con una asesoría, y la de IGC es diferenciada.”
“IGC ha estado junto a Femme durante 13 años y ayudó a la empresa en todas las etapas decisivas. Es un lugar de principios y propósitos, lo que creó una unión entre nosotros.”
Nuestro posicionamiento es claro y único: actuamos exclusivamente en el sell-side. Sin conflictos de interés, siempre al lado del empresario, y con un solo compromiso: el mejor resultado para nuestro cliente.
© 2025 IGC Partners. Todos los derechos reservados. Todo el contenido, los materiales y la información presentados en este sitio tienen únicamente fines informativos y no constituyen asesoramiento legal, financiero, de inversión o profesional. IGC Partners no ofrece ninguna garantía ni declaración, expresa o implícita, en cuanto a la precisión, integridad o idoneidad de la información proporcionada. Los usuarios deben buscar el asesoramiento profesional adecuado antes de actuar sobre la base de cualquier información aquí contenida. Se prohíbe el uso, la reproducción o la distribución no autorizados de cualquier parte de este sitio. Al acceder y utilizar este sitio, usted acepta nuestra Política de privacidad y nuestros Términos de uso. Para obtener más información, utilice los canales proporcionados en nuestra página de contacto.